Edition:
United States

Novelion Therapeutics Inc (NVLN.OQ)

NVLN.OQ on NASDAQ Stock Exchange Global Select Market

4.17USD
3:59pm EST
Change (% chg)

$0.07 (+1.71%)
Prev Close
$4.10
Open
$4.14
Day's High
$4.24
Day's Low
$4.10
Volume
5,438
Avg. Vol
18,789
52-wk High
$12.09
52-wk Low
$3.10

Select another date:

Thu, Feb 1 2018

BRIEF-Partner Therapeutics Acquires Leukine From Sanofi

* PARTNER THERAPEUTICS INC - HAS ACQUIRED GLOBAL RIGHTS TO DEVELOP, MANUFACTURE, AND COMMERCIALIZE LEUKINE (SARGRAMOSTIM) FROM SANOFI

BRIEF-Novelion Says U.S. District Court Judge Sentenced Unit Aegerion Pharmaceuticals

* NOVELION THERAPEUTICS INC - ANNOUNCED THAT A U.S. DISTRICT COURT JUDGE HAS SENTENCED NOVELION SUBSIDIARY AEGERION PHARMACEUTICALS

U.S. judge sentences Novelion's Aegerion in drug marketing case

BOSTON A federal judge on Tuesday sentenced Aegerion Pharmaceuticals Inc for improperly marketing a cholesterol drug and ordered that some of the $40.1 million it agreed to pay to resolve a U.S. investigation go to the company's victims.

UPDATE 1-U.S. judge sentences Novelion's Aegerion in drug marketing case

BOSTON, Jan 30 A federal judge on Tuesday sentenced Aegerion Pharmaceuticals Inc for improperly marketing a cholesterol drug and ordered that some of the $40.1 million it agreed to pay to resolve a U.S. investigation go to the company's victims.

Novelion's Aegerion faces sentencing in U.S. drug marketing case

BOSTON, Jan 30 Aegerion Pharmaceuticals Inc is set to be sentenced on Tuesday for improperly marketing a cholesterol drug by a judge who rejected an initial plea deal and asked whether the drugmaker should be allowed to "collapse in disgrace."

BRIEF-Novelion Therapeutics Announces Cost Reduction Plans, Capital Structure Review

* NOVELION THERAPEUTICS ANNOUNCES COST REDUCTION PLANS AND CAPITAL STRUCTURE REVIEW

Novelion unit asks U.S. judge to approve plea deal, cites money woes

BOSTON Aegerion Pharmaceuticals Inc has asked a U.S. judge to quickly approve a new plea agreement aimed at resolving probes into its promotion of a cholesterol drug, saying its parent company has been blocked from capital markets due to the case's uncertainty.

Novelion unit asks U.S. judge to approve plea deal, cites money woes

BOSTON, Dec 22 Aegerion Pharmaceuticals Inc has asked a U.S. judge to quickly approve a new plea agreement aimed at resolving probes into its promotion of a cholesterol drug, saying its parent company has been blocked from capital markets due to the case's uncertainty.

BRIEF-Aspen Announces Strategic Partnership With CGB Diversified Services

* ASPEN ANNOUNCES STRATEGIC PARTNERSHIP WITH CGB DIVERSIFIED SERVICES

BRIEF-Edgepoint Investment Group Reports 10.6 Pct Passive Stake In Novelion Therapeutics

* EDGEPOINT INVESTMENT GROUP INC REPORTS 10.6 PERCENT PASSIVE STAKE IN NOVELION THERAPEUTICS INC AS OF NOVEMBER 30 - SEC FILING Source text : http://bit.ly/2yOFk6N Further company coverage:

Select another date: